Menu Search
Equities

Amedisys Inc

ADY:DUS

Amedisys Inc

Actions
  • Price (EUR)88.50
  • Today's Change0.50 / 0.57%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 18:31 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Amedisys, Inc. is a healthcare service company. The Company is engaged in providing care and support in the home. It delivers clinically distinct care that suits its patients' needs, whether that is home-based recovery and rehabilitation after an operation or injury or care. Its operations involve serving patients across the United States through its three operating divisions: home health, hospice, and high acuity care. Its home health segment provides compassionate healthcare to help its patients recover from surgery or illness, live with chronic diseases, and prevent avoidable hospital readmissions. The home health includes 346 care centers located in 34 states within the United States and the District of Columbia. Its hospice care is designed to provide comfort and support for those who are dealing with a terminal illness. Its high acuity care segment delivers the essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes.

  • Revenue in USD (TTM)2.32bn
  • Net income in USD82.93m
  • Incorporated1994
  • Employees19.00k
  • Location
    Amedisys Inc5959 S SHERWOOD FOREST BLVDBATON ROUGE 70816United StatesUSA
  • Phone+1 (225) 292-2031
  • Fax+1 (302) 636-5454
  • Websitehttps://www.amedisys.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.